Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × selinexor × Other solid neoplasm × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 10 CNS 3 Thoracic 2 Sarcoma 2 Other hematologic neoplasm 2 Lymphoid 2 Gastrointestinal 2 Other solid neoplasm 1 Genitourinary 1 Breast 1

Conditions

Solid Tumor Malignancy 1

Interventions

pembrolizumab 37 Injections 33 toripalimab 20 Bevacizumab 16 Nivolumab 15 Cisplatin 15 Pemetrexed 14 Paclitaxel 14 Cyclophosphamide 14 Carboplatin 14 fludarabine 9 Irinotecan 9 Ipilimumab 9 tislelizumab 8 Leucovorin 8 Gemcitabine 8 Fluorouracil 8 Docetaxel 8 atezolizumab 7 spartalizumab 6 Oxaliplatin 6 Albumin-Bound Paclitaxel 5 trifluridine tipiracil drug combination 4 sintilimab 4 palbociclib 4 lenvatinib 4 Radiosurgery 4 Interleukin-2 4 Fulvestrant 4 Capecitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Hackensack Meridian Health

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡